GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
NEW YORK, Nov. 15, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Diplomat Pharmacy, Inc. (NYSE:DPLO) securities between October 9, 2014 and November 2, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/diplomat-pharmacy. There is no cost or obligation to you.
According to the complaint, during the Class Period, Diplomat Pharmacy issued false and misleading statements to investors and/or failed to disclose that: (1) the Company lacked adequate internal controls over its financial reporting and thus could not adequately calculate DIR fees; (2) Diplomat Pharmacy’s hepatitis C segment was not performing as previously disclosed to investors; (3) the Company overstated its full-year 2016 guidance; and (4) as a result of the above, Diplomat Pharmacy’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
On November 2, 2016, Diplomat Pharmacy announced third quarter 2016 results that were below investors’ expectations and lowered its full year 2016 guidance. When this news was announced, shares of Diplomat Pharmacy fell in value, harming investors.
If you suffered a loss in Diplomat Pharmacy you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/diplomat-pharmacy.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
